SCHEMBL4469357

SCHEMBL4469357

Fc1ccc(Oc2ccc(-c3c[nH]c(COc4ccccc4)n3)cc2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.42
GRM5 P41594 1/20 0.41
FFAR4 Q5NUL3 4/20 0.41
FFAR1 O14842 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
XDH P47989 2/20 0.40
PPARG P37231 2/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
LTA4H P09960 1/20 0.37
PLA2G2A P14555 1/20 0.37
RAB9A P51151 3/20 0.37
NPC1 O15118 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272423 0.90 XDH (0.43) MCL1GRM5FFAR4FFAR1XDH
Hydrochloric Acid SCHEMBL4458287 0.89 XDH (0.42) MCL1GRM5FFAR4FFAR1XDH
SCHEMBL4686964 0.89 MCL1 (0.46) MCL1POLBL3MBTL1XDHLTA4H
SCHEMBL4460356 0.88 LOXL2 (0.42) MCL1GRM5FFAR4FFAR1XDH
SCHEMBL4460188 0.88 NPC1 (0.45) MCL1GRM5L3MBTL1XDHLOXL2
SCHEMBL4460441 0.87 MCL1 (0.42) MCL1FFAR4L3MBTL1XDHPPARG
SCHEMBL4459880 0.86 RAB9A (0.44) MCL1POLBL3MBTL1XDHPPARG
SCHEMBL4463577 0.85 PPARG (0.40) MCL1GRM5FFAR4POLBL3MBTL1
SCHEMBL3270549 0.85 MCL1 (0.37) MCL1GRM5FFAR4FFAR1L3MBTL1
SCHEMBL4458363 0.85 MCL1 (0.38) MCL1FFAR4L3MBTL1XDHPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US claimed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP claimed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US claimed
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 MCL1 2/4885GRM5 2639/4885FFAR4 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.